Abstract
Neuroendocrine tumors encompass a wide spectrum of neoplasms with a common origin in the neuroendocrine cell system. They share the capacity for hormone secretion that results in distinct clinical syndromes. Although neuroendocrine tumors can arise in organs such as the adenohypophysis, thymus, lung, thyroid, adrenal medulla/paraganglia, and skin (1), most familiar are the gastroenteropancreatic neuroendocrine tumors that include carcinoid and islet cell neoplasms. Given the high occurrence of hepatic metastases within this subgroup of neuroendocrine tumors, they are a model for the management of other hormonally active tumors.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
DeLellis RA, Tischler AS. The dispersed neuroendocrine system. In: Kovacs K, Asa SL, eds. Functional Endocrine Pathology. Malden, MA: Blackwell Science, 1998:529–549.
Oberg K. State of the art and future prospects in the management of neuroendocrine tumors. Q J Nucl Med 2000;44:3–12.
Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997;79:813–829.
Shebani KO, Souba WW, Finkelstein DM, et al. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 1999;229:815–821; discussion 822–823.
Proye C. Natural history of liver metastasis of gastroenteropancreatic neuroendocrine tumors: place for chemoembolization. World J Surg 2001;25:685–688.
Moertel CG. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 1987;5:1502–1522.
Moertel CG, Sauer WG, Dockerty MB, Baggenstoss AH. Life history of the carcinoid tumor of the small intestine. Cancer 1961;14:901–912.
Thompson GB, van Heerden JA, Grant CS, Carney JA, Ilstrup DM. Islet cell carcinomas of the pancreas: a twenty-year experience. Surgery 1988;104:1011–1017.
Carty SE, Jensen RT, Norton JA. Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery 1992;112:1024–1031; discussion 1031–1032.
Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995;169:36–42; discussion 42–43.
Grazi GL, Cescon M, Pierangeli F, et al. Highly aggressive policy of hepatic resections for neuroendocrine liver metastases. Hepatogastroenterology 2000;47:481–486.
Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 1998;187:88–92; discussion 92–93.
Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. Journal Amer Coll Surgeons 2003;197(1):29–37.
Que FG, Heywood GM. Hepatic surgery for metastatic gastrointestinal neuroendocrine tumors. In: Blumgart LH, Fong Y, Jarnagin W, eds. Hepatobiliary Cancer. American Cancer Society and B.C. Dekker, 2000;97–116.
McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990;108:1091–1096.
Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000;190:432–445.
Brown KT, Koh BY, Brody LA, et al. Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Intervent Radiol 1999;10:397–403.
Eriksson BK, Larsson EG, Skogseid BM, Lofberg AM, Lorelius LE, Oberg KE. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998;83:2293–2301.
Moertel CG, Johnson CM, McKusick MA, et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 1994;120:302–309.
Seifert JK, Cozzi PJ, Morris DL. Cryotherapy for neuroendocrine liver metastases. Semin Surg Oncol 1988;14:175–183.
Cozzi PJ, Englund R, Morris DL. Cryotherapy treatment of patients with hepatic metastases from neuroendocrine tumors. Cancer 1995;76:501–509.
Bilchik AJ, Sarantou T, Foshag LJ, Giuliano AE, Ramming KP. Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy. Surgery 1997;122:1040–1047; discussion 1047–1048.
Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 2002;26:985–990.
Hellman P, Ladjevardi S, Skogseid B, Akerstrom G, Elvin A. Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg 2001;26:1052–1056.
Wessels FJ, Schell SR. Radiofrequency ablation treatment of refractory carcinoid hepatic metastases. J Surg Res 2001:95:8–12.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
Atwell, T.D., Charboneau, J.W., Nagorney, D.M., Que, F.G. (2005). Radiofrequency Ablation of Neuroendocrine Metastases. In: vanSonnenberg, E., McMullen, W.N., Solbiati, L., Livraghi, T., Müeller, P.R., Silverman, S.G. (eds) Tumor Ablation. Springer, New York, NY. https://doi.org/10.1007/0-387-28674-8_27
Download citation
DOI: https://doi.org/10.1007/0-387-28674-8_27
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-95539-1
Online ISBN: 978-0-387-28674-7
eBook Packages: MedicineMedicine (R0)